2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1575

Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Abstract Number: 1635

Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity
Abstract Number: 2729

Identification Of Osteoarthritis Patients With Chronic Inflammation Driven Disease Progression
Abstract Number: 1857

Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model
Abstract Number: 554

Identification Of Stage Specific Genes Associated With Lupus Nephritis and Response To Remission induction In NZB/W Mice
Abstract Number: 111

Identifying Groups At Increased Risk Of Developing Rheumatoid Arthritis Using Family History and Genetic Risk Scores
Abstract Number: 129

Identifying Predictors Of A Fibromyalgia Diagnosis: A Retrospective Electronic Medical Record Analysis
Abstract Number: 1744

Identifying Trajectories of Lung Function Change Over Time in Scleroderma
Abstract Number: 36

IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Abstract Number: 2636

IgA Vasculitis – The Second Most Common Systemic Vasculitis In Adults In Slovenia
Abstract Number: 2635

IgA Vasculitis In Adults – a Rare and Benign Disease?
Abstract Number: 31

IgD- CD27- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor 3 Signaling Pathways
Abstract Number: 2654

IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Abstract Number: 1099

IgG Autoantibodies Against p29ING4 In Early-Stage Type I Complex Regional Pain Syndrome (CRPS) and In Other Inflammatory Diseases Involving The Joints
Abstract Number: 2023

IgG4-Related Midline Destructive Lesion: Expanding The Spectrum Of Organ Involvement In IgG4-Related Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].